Moxonidine 0.2 MG

DRUG2 trials

Sponsors

Italo Biaggioni, Royal Perth Hospital

Conditions

Central Sympathetic Nervous System DiseasesObesity-Associated Insulin Resistance

Phase 1

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

TerminatedNCT04329806

Italo BiaggioniObesity-Associated Insulin Resistance

Start: 2021-02-23End: 2022-07-27Updated: 2025-09-05

Phase 4

Role of Sympathetic Activation in Ischemia Reperfusion Injury

CompletedNCT04479813

Royal Perth HospitalCentral Sympathetic Nervous System Diseases

Start: 2015-07-08End: 2022-03-01Updated: 2022-09-29